12:00 AM
 | 
Jun 01, 2009
 |  BC Week In Review  |  Company News  |  Other News

CSL, U.S. Department of Health and Human Services infectious news

CSL's CSL Biotherapies subsidiary will receive $180 million from HHS under a contract to produce bulk supply of H1N1 influenza vaccine antigen. Last month, HHS announced it would appropriate $1 billion...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >